Ge Li

Ge Li, also known as Gé Lǐ or Li Ge, is a Chinese-American entrepreneur, pharmaceutical-services executive, and philanthropist. He is best known as the co-founder and chairman of WuXi AppTec, a China-based contract research, development, and manufacturing organization serving pharmaceutical and biotechnology companies. WuXi AppTec provides services across drug discovery, development, testing, process research, and manufacturing, making Li a prominent figure in the global outsourced life-sciences industry. Li was born in Beijing, China. He attended the Affiliated High School of Peking University and earned a bachelor's degree from Peking University in 1989. He later moved to the United States and completed a Ph.D. in organic chemistry at Columbia University in 1994, studying under the chemists W. Clark Still and Koji Nakanishi. His scientific training shaped the technical and research-oriented character of his later business activities. Before founding WuXi AppTec, Li worked at Pharmacopeia, Inc., a pharmaceutical research company. During that period, he traveled to China to explore the establishment of a joint business venture. The experience contributed to his decision to leave Pharmacopeia and establish a China-based research-services company. In 2000, Li co-founded WuXi AppTec in Shanghai with his wife, Ning Zhao. The company developed from a Chinese research-services provider into an international platform supporting pharmaceutical and biotechnology clients. WuXi AppTec expanded its international presence over time. In 2016, it opened a facility in San Diego, California, providing small-molecule screening, discovery biology, process research and development, and Phase I Good Manufacturing Practice services for North American customers. The company was initially listed in New York before moving its public listing to Hong Kong in 2018. Li's role has centered on the company's strategic direction, international growth, and position within the global pharmaceutical-services ecosystem. Li has also participated in Chinese-American civic and professional networks. In 2011, he was selected as a member of the Committee of 100, an organization of prominent Chinese Americans. His public profile increased as WuXi AppTec grew and as the company became part of debates over biotechnology supply chains, data security, and the strategic role of Chinese life-sciences enterprises. His philanthropic activities have focused on education, chemistry, and medical research. In 2018, Li and Zhao donated 100 million renminbi to Peking University to establish the Li Ge-Zhao Ning Education Fund, after which they were named honorary trustees of the university. In 2020, the couple donated $21.5 million to Columbia University for research and chemistry teaching. In 2021, they contributed $20 million to Memorial Sloan Kettering Cancer Center for lung-cancer research. Li has also faced heightened public scrutiny because of proposed United States legislation concerning WuXi AppTec. In February 2024, he co-signed an open letter rejecting what the company characterized as broad allegations and preemptive measures. The BIOSECURE Act, passed by the U.S. House of Representatives in 2024, specifically identified WuXi AppTec in connection with concerns about foreign-adversary links. Analyses cited in public reporting have examined Li's participation in Chinese Communist Party-related activities and the relationship between WuXi's corporate role and China's national technology objectives. These issues have affected perceptions of the company and its leadership but do not change Li's role as WuXi AppTec's co-founder and chairman.

Ge Li was born in Beijing and completed his early education at the Affiliated High School of Peking University. He graduated from Peking University in 1989 with a bachelor's degree and subsequently went to the United States for doctoral study. In 1994, he earned a Ph.D. in organic chemistry from Columbia University, where his mentors included W. Clark Still and Koji Nakanishi. Li began his professional career in the pharmaceutical research sector at Pharmacopeia, Inc. While working there, he traveled to China to explore the creation of a joint business venture. The trip exposed him to opportunities to build a research-services organization linking Chinese scientific capacity with the needs of international pharmaceutical companies. In 2000, he left Pharmacopeia and co-founded WuXi AppTec in Shanghai with his wife, Ning Zhao. Under Li's leadership, WuXi AppTec developed into a contract research, development, and manufacturing organization. Its activities have included drug discovery, small-molecule screening, discovery biology, process research and development, testing, and manufacturing support. The company's model allowed pharmaceutical and biotechnology customers to outsource portions of research and development while accessing scientific and manufacturing capabilities in China and other markets. WuXi AppTec later expanded outside China. In 2016, the company opened a San Diego facility serving North American clients. The site supported small-molecule screening, discovery biology, process research and development, and Phase I Good Manufacturing Practice services. The company's corporate development also included a transition from a New York Stock Exchange listing to a Hong Kong Stock Exchange listing in 2018. Li's public activities have extended beyond corporate management. In 2011, he became a member of the Committee of 100, a network of Chinese Americans in professional and civic life. Together with Zhao, he supported educational and medical institutions through substantial donations. Their 2018 gift to Peking University created the Li Ge-Zhao Ning Education Fund. Further gifts supported chemistry and research at Columbia University in 2020 and lung-cancer research at Memorial Sloan Kettering Cancer Center in 2021. Li's leadership became a subject of geopolitical controversy as governments and policymakers examined the security implications of biotechnology supply chains involving Chinese companies. In February 2024, he co-signed a letter opposing proposed measures directed at WuXi AppTec. The company was specifically named in the BIOSECURE Act passed by the United States House of Representatives in 2024. Public analyses have debated Li's relationship with Chinese Communist Party activities and the company's relationship to China's national scientific and strategic goals. These concerns have placed Li and WuXi AppTec at the intersection of pharmaceutical outsourcing, international trade, and national-security policy. Ning Zhao, Li's wife and business partner, formerly served as WuXi AppTec's senior vice president and global head of human resources. She died on May 16, 2023, following a 20-year illness. Li remains identified with WuXi AppTec as its co-founder and chairman.

• 2024

  Responds to proposed United States biotechnology restrictions

  [1]Ge Lien.wikipedia.org

  Li co-signs a letter opposing proposed measures targeting WuXi AppTec amid national-security concerns.

• 2018

  WuXi AppTec lists in Hong Kong

  [1]Ge Lien.wikipedia.org

  The company's public-market listing moves from the New York Stock Exchange to the Hong Kong Stock Exchange.

• 2018

  Creates education fund at Peking University

  [1]Ge Lien.wikipedia.org

  Li and Zhao donate 100 million renminbi to establish the Li Ge-Zhao Ning Education Fund.

• 2016

  WuXi AppTec opens San Diego facility

  [1]Ge Lien.wikipedia.org

  The company expands its North American capabilities in research, development, and early-stage manufacturing support.

• 2011

  Joins the Committee of 100

  [1]Ge Lien.wikipedia.org

  Li is selected as a member of the Chinese-American professional and civic organization.

• 2000

  Co-founds WuXi AppTec

  [1]Ge Lien.wikipedia.org

  Li leaves Pharmacopeia and establishes WuXi AppTec in Shanghai with Ning Zhao.

• 1994

  Earns a doctorate in organic chemistry

  [1]Ge Lien.wikipedia.org

  Li completes a Ph.D. in organic chemistry at Columbia University.

• 1989

  Graduates from Peking University

  [1]Ge Lien.wikipedia.org

  Li receives a bachelor's degree from Peking University.

Li is associated with WuXi AppTec's positioning as an integrated, internationally oriented contract research, development, and manufacturing partner for pharmaceutical and biotechnology companies.

• Contract pharmaceutical research, development, and manufacturing · 2000

  WuXi AppTec integrated services

  WuXi AppTec operates as a contract research, development, and manufacturing organization for pharmaceutical and biotechnology customers. Its integrated scope spans discovery, development, testing, process research, and manufacturing support, allowing clients to outsource selected stages or combine multiple services through one provider.

• Drug discovery services

  Small-molecule screening and discovery biology

  These services support early pharmaceutical research, including the screening of small molecules and biological investigation used to identify and assess potential drug candidates.

• Pharmaceutical development services

  Process research and development

  Process research and development helps pharmaceutical clients develop and refine methods for producing drug substances and related materials before and during manufacturing scale-up.

• Clinical manufacturing services · 2016

  Phase I GMP services

  The San Diego operation has supported Phase I Good Manufacturing Practice services for North American clients, linking early clinical development with regulated production capabilities.

• 2024

  WuXi AppTec national-security controversy

  WuXi AppTec became a focus of United States national-security and biotechnology-supply-chain concerns. The BIOSECURE Act passed by the U.S. House of Representatives specifically named the company in provisions concerning entities alleged to have ties to a foreign adversary's military, internal-security forces, or intelligence agencies. Li co-signed a February 2024 letter rejecting broad allegations and preemptive measures, while external analyses examined his participation in Chinese Communist Party-related activities and WuXi's role in China's strategic science and technology objectives.

  Source

Read more

• 2024

  Publicly contests proposed restrictions on WuXi AppTecStrategy

  Background

  WuXi AppTec faced proposed United States measures linked to allegations concerning foreign-adversary influence and national-security risks.

  Action taken

  Li co-signed an open letter rejecting blanket allegations and preemptive actions against the company.

  Aftermath

  The controversy continued as the BIOSECURE Act passed the U.S. House of Representatives and WuXi AppTec remained part of the debate over biotechnology supply chains.

  Source

• 2018

  Moves WuXi AppTec's public listing to Hong KongOther

  Background

  WuXi AppTec had previously been listed on the New York Stock Exchange.

  Action taken

  The company became listed on the Hong Kong Stock Exchange.

  Aftermath

  The move established Hong Kong as the company's reported public-market listing venue.

  Source

• 2016

  Expands WuXi AppTec into North AmericaStrategy

  Background

  The company sought to extend its research and development services beyond China and serve North American pharmaceutical customers directly.

  Action taken

  WuXi AppTec opened a San Diego facility supporting discovery, process development, and Phase I GMP activities.

  Aftermath

  The facility broadened the company's international operating footprint and its direct support for North American clients.

  Source

• 2000

  Establishes a China-based pharmaceutical research platformStrategy

  Background

  After working at Pharmacopeia and traveling to China to explore a joint venture, Li identified an opportunity to build an international pharmaceutical-services company in Shanghai.

  Action taken

  Li and Ning Zhao left their prior professional positions and co-founded WuXi AppTec.

  Aftermath

  WuXi AppTec grew into an integrated contract research, development, and manufacturing organization serving pharmaceutical and biotechnology clients.

  Source

• Unconfirmed

  Q CELLS announces acquisition of Geli[2]Q CELLS宣布收购Gelisocaltech.com

  Q CELLS said it is acquiring Geli, an energy storage software maker. Financial terms were not announced.

Read more

1. 1Ge Lien.wikipedia.org
2. 2Q CELLS宣布收购Gelisocaltech.com